Advanced in Medical Technology

Medigus and Tower Semiconductor Announce World's Smallest Medical Video Camera Based on Advanced CMOS Image Sensor

OMER and MIGDAL HA'EMEK, Israel, August 3 /PRNewswire-FirstCall/ -- Medigus Ltd. (TASE: MDGS) a leading developer of endoscopic and visualization medical devices, and Tower Semiconductor, Ltd. (Nasdaq: TSEM , TASE: TASE: TSEM), a leading global specialty foundry, today announced successful s...

OPAXIO(TM) Combined with Alimta(R) Well Tolerated in Dose-Ranging Study of Patients with Advanced Non-Small Cell Lung Cancer

SEATTLE, Aug. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced results from a study released by Dartmouth-Hitchcock Medical Center at the International Association for the Study of Lung Cancer (IASLC) 13th World Conference on Lung Cancer. Th...

CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer

- 12 week progression free rate supports advancement into second stage of Simon 2-Stage designed trial - BRANFORD, Conn., June 17 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN ) announced today that its Phase I/II Trial evaluating CR011-vcMMAE for the treatment of patients w...

PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)

ANNAPOLIS, Md., June 2 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP ), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that it has submitted a proposal to the Biomedical Advanced Research and Development Authority (B...

Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients

-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program -- SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced the presentation of new clinical results from a Phase 1-...

Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

KRX-0401 + Capecitabine More Than Doubles Time to Progression and Overall Response Rate as well as Extends Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer NEW YORK, June 1 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasda...

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

Recently Expanded Clinical Program Now Includes Solid and Hematological Malignancies ROCKVILLE, Md., June 1 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation ...

Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

KRX-0401 + Capecitabine More Than Doubled Time to Progression and Overall Response Rate as well as Extended Overall Survival vs. Capecitabine + Placebo in Patients with 2nd or 3rd Line Metastatic Colon Cancer NEW YORK, May 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc. today reported on clinical advances for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the American S...

Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology

ORLANDO, Fla., May 30 Data from the Phase III ZODIAC study in advanced non-small cell lung cancer patients, with the investigational drug vandetanib, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Orlando. Results show that the study met its primary endpoint, d...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

- Phase 3 study has demonstrated that Induction Chemotherapy prior to ChemoRadiotherapy significantly increased time-to-treatment failure in comparison to standard ChemoRadiotherapy alone - MADRID, May 30 /PRNewswire/ -- The Spanish Head and Neck Cancer Cooperative Group (TTCC) announced toda...

Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401's Activity in the Treatment of Advanced Metastatic Renal Cell Cancer

KRX-0401 Demonstrates Impressive Single Agent Efficacy in Patients who Progressed after Failing Treatment Either with a VEGF Receptor Inhibitor or after Treatment with both a VEGF Receptor Inhibitor and an mTOR Inhibitor NEW YORK, May 29 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, I...

New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer

COLLEGEVILLE, Pa., May 29 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) bre...

Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients; Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneou...

VA Studies Advanced Prosthetic Arm

New Mobility for Veterans, Service Members, Other Americans WASHINGTON, May 27 /PRNewswire-USNewswire/ -- The Department of Veterans Affairs (VA) has announced a three-year study of an advanced artificial arm that easily allows those with severe limb loss to pick up a key or hold a pencil. ...

Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer

Phase 3 IMPACT Trial Results to be presented during late-breaking session at AUA Annual Scientific Meeting CHICAGO, April 28 /PRNewswire-USNewswire/ -- Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be pr...

Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo - - First Active Cellular Immunotherapy for Cancer to Prolong Survival - - Company to Host Webcast at 5:30 pm ET - CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreo...

Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint

WAYNE, N.J. and EMERYVILLE, Calif., April 27 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that a Phase 3 trial evaluating Nexavar(R) (sorafenib) tablets in patients with unresectable stage III or stage IV melanoma was s...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

Start of trial triggers $10 million milestone payment to Pharmasset PRINCETON, N.J., April 24 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today announced that the first patient has been dosed in a Phase IIb study of R7128, th...

Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients

Sustained Benefits for Patients Awaiting Transplantation ANN ARBOR, Mich., April 7 /PRNewswire/ -- The DuraHeart(TM) Left Ventricular Assist System (LVAS) shows sustained benefits in providing safe and reliable long-term circulatory support with an improved survival rate and an acceptable adv...

Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib

- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - ...

ULURU Inc. to Present Altrazeal(TM) Clinical Evidence and Advanced Therapeutic Research at the Diabetic Foot Global Conference (DFCon) 2009

ADDISON, Texas, March 18 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced that clinical evidence on the treatment of diabetic foot ulcers, and data on the use of its patented Nanoflex(TM) Technology for Therapeutic Delivery will be presented at the annual DFCon Global Meeting...

Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmer's Trabecular Metal(TM) Technology

10-Year Study Highlights Trabecular Metal Technology's Clinical Success Over Traditional Metal Implants WARSAW, Ind., Feb. 25 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ZMH), a leader in the orthopaedic industry, today announced that data from an independent 10-ye...

Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial

GENEVA, Feb. 3 /PRNewswire/ -- -- The Six-Month Primary Efficacy Endpoint of the Study was met: Both Doses of Investigational Agent Safinamide Significantly Increased "ON" Time in Levodopa-Treated Patients With mid- to Late-Stage Parkinson's Disease -- Secondary Efficacy Endpoi...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

OSLO, Norway, January 14 /PRNewswire-FirstCall/ -- - Results Highlight the Potential of Alpharadin to Treat Bone Metastases in Major Cancer Indications Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that with the results of the BC1-04 study reported today i...

New Overall Survival Study Results Confirm Oral Xeloda(R) plus Oxaliplatin (XELOX) is Comparable to FOLFOX-4 for the First-Line Treatment of Advanced Colorectal Cancer

-Growing Body of Data Supports XELOX as Effective Alternative to Standard of Care- NUTLEY, N.J., Jan. 13 /PRNewswire-FirstCall/ -- Overall survival results from a 14-month follow-up of the international, Phase III NO16966 study confirm that oral Xeloda(R) plus oxaliplatin (XELOX) is comp...

RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

- After eight weeks of treatment, RAD001 halted tumor growth in 55% of advanced gastric cancer patients previously treated with chemotherapy - Based on these promising data, Novartis will initiate a Phase III trial of RAD001 for advanced gastric cancer patients - Gastric cancer is the s...

New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients al...

Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions

Phase 1 Data Demonstrate Safety and Improvement in Heart Failure in a Majority of Patients NEW ORLEANS, Nov. 9 /PRNewswire/ -- Celladon Corporation announced today results from the first nine patients treated with MYDICAR(R), a genetically-targeted enzyme replacement ...

Multi-Centre European Clinical Trial Shows Advanced Dysplasia and Early Cancer of Esophagus Cured With Combined Endoscopic Resection and Radiofrequency Ablation With HALO Ablation System

Non-surgical intervention cures 96% of patients with advanced esophagus condition SUNNYVALE, Calif., Oct. 19 /PRNewswire/ -- BARRX Medical, Inc. today announced clinical trial results presented at the United European Gastroenterology Week (UEGW) in Vienna, Austria...

Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program

DALLAS, Oct. 17 /PRNewswire-USNewswire/ -- Elizabeth Krause is a perfectly healthy 40-year-old woman. So it's surprising to learn she has oncologists, breast surgeons, radiologists and nurse practitioners watching over her like an army of cancer-killers, ready to pounce at the first sign of bre...

Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure

Company Targeting to Complete Enrollment of 150 patients by March 2009 SUNRISE, Fla., Sept. 30 /PRNewswire-FirstCall/ -- Bioheart, Inc., (Nasdaq: BHRT ), today announced that 35 of the leading U.S. Heart Failure Centers have engaged in Bioheart's Phase II/III MARVEL(1) Trial of myogenic cel...

MedNet Solutions to Sponsor and Exhibit at the 2008 Advanced Medical Technology Association Conference in Washington, D.C.

MINNETONKA, Minn., Sept. 18 /PRNewswire/ -- MedNet Solutions, a global eClinical technology company specializing in clinical study management systems, today announced the company's active involvement as a sponsor and exhibitor at the 2008 Advanced Medical Technology Association (AdvaMed) MedTe...

Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer

- New data, updated since ASCO, show time without tumor growth now reaches nearly 5 months with RAD001 vs. 1.9 months with placebo - One quarter of patients in trial remained progression-free beyond ten months of treatment - RAD001 is first drug to show significa...

RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer

-- Regulatory applications to be submitted worldwide for RAD001 first submissions filed in the Hidden List US, EU and Switzerland -- Data showing that RAD001 more than doubles time without tumor growth and reduced risk of disease progression by 70% now published in The...

Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma

- First of three ongoing randomized chemotherapy combination trials to evaluate HGS-ETR1 in the treatment of specific cancers - ROCKVILLE, Md., Sept. 2 /PRNewswire-FirstCall/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI ) today reported initial topline results from an ongoing randomiz...

Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma

Potential for data analysis early 2009 SEATTLE, Aug. 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.'s (CTI) (Nasdaq: CTIC ; MTA) subsidiary Systems Medicine (SM) announced today that planned enrollment is complete in the European Organization for Research and Treatment ...

Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer

- Peregrine Achieves Milestone as Third Phase II Trial in Its Bavituximab Cancer Program Begins Patient Enrollment and Dosing - TUSTIN, Calif., Aug. 11 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that patient screening and dosing has begun ...

Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer

SEATTLE, July 23 /PRNewswire/ -- Sound Pharmaceuticals (SPI) has filed an Investigational New Drug Application with the FDA for the clinical testing of a proprietary formulation of ebselen for the prevention of chemotherapy induced hearing loss or ototoxicity. The oral capsule containing ebsel...

Nemours Center for Childhood Cancer Research Team at the Alfred I. duPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer

WILMINGTON, Del., July 17 /PRNewswire/ -- The research team at the Nemours Center for Childhood Cancer Research (NCCCR), a newly established division of Nemours Biomedical Research at the Alfred I. duPont Hospital for Children has discovered that the biomarker called prostate specific membrane...